Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility
Key Inclusion Criteria: * Meets criteria established in locally applicable Vercise System Direction for Use * At least 18 years old Key Exclusion Criteria: * Meets any contraindication in the Vercise System locally applicable Directions for Use Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Conditions1
Locations28 sites
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT02071134